An observational study in Stenoses, Carotid, sponsored by Mayo Clinic. Active, not recruiting at 64 sites in 3 countries. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.
Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 2nd largest by planned enrollment of the 31 observational ones that give a count, is one of 4 that started in 2022, is one of 31 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 78th registered.
369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.
Browse Carotid Stenosis studies →6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:
InspireMD · Sites in United States
Ages 18–79
Mayo Clinic · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–89 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 65+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 7 · Phase 4 5
First in 1993; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,480 is above the median of 176 across 161 observational studies indexed under Carotid Stenosis.
Median enrollment 69 across the 53 interventional studies, 114 across the 31 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 84 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 5 studies filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Carotid Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851389Vibrant Medical Ltd.A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies | 2027-03 |
| NCT04063709University of North Carolina, Chapel HillTranscutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk | 2027-08 |
| NCT05465122Mayo ClinicCREST-2 Long-term Observational Extension Study | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 84 studies in Carotid Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial (C2LOE - ClinicalTrials.gov Identifier: NCT02089217) study is to study is to assess post-procedural efficacy of carotid endarterectomy and carotid stenting.
Atherosclerotic plaque in the carotid arteries is responsible for 10 to 15% of all ischemic strokes. The ongoing NINDS-funded CREST-2 multicenter randomized clinical trial is testing whether in the short term (up to 4 years after study entry) procedural revascularization improves stroke prevention above and beyond what can be achieved with intensive medical management of vascular risk factors, especially hypertension and hyperlipidemia. Our proposal is for an observational extension of the CREST-2 clinical trial to test whether revascularization improves stroke prevention in the clinically relevant long term (up to 8 to 10 years). The current application proposes to use a site-less, centralized telephone approach to extend the follow-up of CREST-2 trial participants for assessing the primary study outcome (stroke) for up to 10 years. The average follow-up will increase from between 2-3 years (clinic-based randomized trial) to 7-8 years (observational extension). Each patient will be contacted by telephone at 6-month intervals, and queried regarding all hospitalizations since the last contact. Suspected stroke events will be adjudicated by an expert clinical events committee based on medical record review.
Patients with asymptomatic carotid stenosis previously randomized in the CREST-2 trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects assigned to the intensive medical management with carotid stenting group in the CREST-2 study (NCT02089217)
Procedure: FDA-approved carotid stents · Other: Intensive Medical Management
Subjects assigned to the intensive medical management with carotid endarterectomy group in the CREST-2 study (NCT02089217)
Procedure: Carotid Endarterectomy · Other: Intensive Medical Management
Subjects assigned to the intensive medical management alone with no carotid stenting (CAS) group in the CREST-2 study (NCT02089217)
Other: Intensive Medical Management
Subjects assigned to the intensive medical management alone with no carotid endarterectomy (CEA) group in the CREST-2 study (NCT02089217)
Other: Intensive Medical Management
This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.
INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.
Stroke
Number of participants to experience a stroke
Time frame: 5 years
Plan to share: No
Started Jul 2022 (actual). Primary completion is estimated for Aug 2027, 61 months after the start.
Of 79 non-industry observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 104. This study's planned 61 months is above that.
Counting every sponsor, half of 87 studies reached it within 50 months; a quarter within 30 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.